Summary
Merck & Co., Inc. reported strong sales growth of 4% to $48.0 billion for the fiscal year ended December 31, 2011, driven by key products like Januvia, Janumet, and Singulair, along with contributions from their Animal Health division and the launch of Victrelis. The company continued its strategic focus on accelerating revenue growth and cost efficiencies through its Merger Restructuring Program, which is on track to deliver substantial savings. Despite facing patent expirations for some products and the ongoing impact of healthcare reforms and European austerity measures, Merck demonstrated resilience. The company also advanced its research and development pipeline, with several new drug candidates under regulatory review and in late-stage development, signaling a commitment to future growth.
Financial Highlights
51 data points| Revenue | $48.05B |
| Cost of Revenue | $16.87B |
| Gross Profit | $31.18B |
| R&D Expenses | $8.47B |
| SG&A Expenses | $13.73B |
| Interest Expense | $695.00M |
| Net Income | $6.27B |
| EPS (Basic) | $2.04 |
| EPS (Diluted) | $2.02 |
| Shares Outstanding (Basic) | 3.07B |
| Shares Outstanding (Diluted) | 3.09B |
Key Highlights
- 1Merck reported a 4% increase in worldwide sales, reaching $48.0 billion in 2011, primarily driven by strong performance in diabetes treatments (Januvia, Janumet), Singulair, and Gardasil.
- 2The company continued its global restructuring program aimed at optimizing costs, having realized approximately $2.9 billion in annual net cost savings since the merger and expecting further savings.
- 3Merck's R&D pipeline showed progress with 19 drug candidates in Phase III development, and plans to file for approval of five major products between 2012 and 2013.
- 4Healthcare reform in the U.S. impacted revenues through increased Medicaid rebates and the Medicare Part D coverage gap discount, totaling approximately $329 million.
- 5European austerity measures and pricing actions negatively affected sales in the EU, a trend Merck anticipates will continue.
- 6The company announced a quarterly dividend increase to $0.42 per share, reflecting confidence in its financial position.
- 7Key products like Singulair and Maxalt are nearing patent expiration, with significant sales declines expected post-expiration, highlighting the importance of the R&D pipeline.